~~<i id='CB6CB4F7DA'><strike id='CB6CB4F7DA'><tt id='CB6CB4F7DA'><pre id='CB6CB4F7DA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

knowledge

author：knowledge 2025-09-30 14:10:10 - browse：9

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： NIH confirmation hearing shows politicization of research

entertainment

leisure time

focus

leisure time

AstatinadayreducestheriskofheartdiseaseinyoungerpeoplelivingwithHIV,accordingtoanewstudypublishedSun

WSS

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Doctors have an ethical obligation to be advocates

The explosion of genetic testing requires a new approach

Where does female orgasm come from? Scientists think they know

STAT Summit: GSK CEO on pharma giant's new direction

Pharmacists can make shortage drugs, but at what cost?

Wikipedia

knowledge

entertainment

Continuity nursing helped my family in our darkest PICU moments

Beam Therapeutics to lay off 20% of its staff, re

Psychedelics group wrestles with new pharma identity

Burning questions about Delta and the next phase of the Covid pandemic

Activists slam private health insurers over coverage restrictions

Inside the culture of fear in the White House science office of Eric Lander

After affirmative action ruling, medical educators look to 'holistic review'

2023 STAT Wunderkinds: get to know the winners

Supreme Court strikes down use of affirmative action

HHS leader on health, climate change and biopharma emissions

leisure time

FDA gives detailed accounting of AI

FDA struggles to regulate food additives, sometimes for decades

FDA warns J&J's Abiomed: We will regulate your software

Will Ozempic

The explosion of genetic testing requires a new approach

The response to Covid

leisure time

leisure time

focus

leisure time